NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109666&from=3 CLASS PERIO ...

RADNOR, Pa., Oct. 29, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Edw ...

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims related to misleading statements about the company's TAVR platform and its market demand [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation, et al., No. 24-cv-02221 [2]. - Investors have until December 13, 2024, to request to lead the case [2]. Group 2: Company Overview - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, as well as critical care monitoring solutions, categorizing its offerings into four main areas: TAVR, TMTT, Surgical Structural Heart therapies, and Critical Care therapies [3]. Group 3: Allegations and Impact - The complaint alleges that Edwards misrepresented the demand for its TAVR platform, claiming significant unmet demand while the actual growth had stalled due to ineffective patient activation activities and prioritization of other treatments by healthcare organizations [4]. - On July 24, 2024, Edwards reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for the second quarter, leading to a 31% decline in stock price from $86.95 to $59.70 per share [5][6]. Group 4: Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs, with a contingency fee structure meaning no upfront costs for shareholders [7][8].

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/edwards-lifesciences-l ...

Core Viewpoint - Edwards Lifesciences Corporation is facing a class action lawsuit due to allegations of misleading investors regarding the growth prospects of its Transcatheter Aortic Valve Replacement (TAVR) platform [1][3]. Group 1: Company Disclosures and Performance - Throughout the class period, Edwards Lifesciences assured investors of "strong sustainable growth" for the TAVR platform, projecting healthy double-digit growth and the potential for acceleration in 2025 and beyond [2]. - The company later revealed that TAVR sales grew only 5% and reduced its growth guidance from 8-10% to 5-7% [4]. - The decline in TAVR growth was attributed to increased competition from structural heart therapies, which impacted hospital workflows [4]. Group 2: Investor Reactions and Market Impact - Following the disappointing Q2 2024 results, analysts downgraded Edwards Lifesciences shares and lowered their price targets, questioning the company's explanations regarding physician capacity versus demand [4]. - The share price dropped by $27.25, a decrease of 31%, resulting in a loss of over $16 billion in shareholder value in a single day [4]. Group 3: Legal and Investigative Actions - Hagens Berman is investigating whether Edwards Lifesciences misled investors about the TAVR business and growth prospects amid increasing competition [5]. - The firm encourages investors who suffered losses to submit their claims and provides information for whistleblowers with non-public information [5].

Have you evaluated the performance of Edwards Lifesciences' (EW) international operations during the quarter that concluded in September 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gr ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards ...

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), of the important December 13, 2024 lead plaintiff deadline. SO WHAT: If you purchased Edwards securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

I discussed my "Strong Buy" thesis on Edwards Lifesciences Corporation (NYSE: EW ) in July 2024 and bought the dip after the company cut its guidance in Q2 FY24 . Since then, the stock price has surged by Analyst's Disclosure: I/we have a beneficial long position in the shares of EW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationshi ...

Core Insights - Edwards Lifesciences Corporation is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business and operations during the Class Period from February 6, 2024, to July 24, 2024 [1][3] Financial Performance - On July 24, 2024, Edwards Lifesciences reported fiscal second quarter 2024 results that fell below expectations and lowered projections for its core Transcatheter Aortic Valve Replacement (TAVR) platform for the full fiscal year 2024 [2] - Following the announcement, the stock price of Edwards Lifesciences dropped by $27.25, or 31.34%, closing at $59.70 per share on July 25, 2024 [2] Allegations in the Lawsuit - The class action complaint alleges that the Company did not have reliable information regarding projected revenue and growth, and that its growth was at risk of deceleration [3] - It is claimed that the Company's "patient activation activities" did not effectively target the low-treatment-rate population necessary for TAVR's growth, and that the Company overstated hospital interest in TAVR procedures compared to newer structural heart therapies [3] - The lawsuit asserts that the positive statements made by the Company about its business and prospects were materially misleading and lacked a reasonable basis [3]